This Study Will Evaluate the Safety, Tolerability, and Efficacy of ANB032 in Subjects With Moderate to Severe Atopic Dermatitis (AD).
Atopic Dermatitis Eczema
About this trial
This is an interventional treatment trial for Atopic Dermatitis Eczema focused on measuring ANB032, B and T lymphocyte attenuator BTLA
Eligibility Criteria
Key Inclusion Criteria: Male or female aged 18 to 65 years and in good general health Moderate to severe AD for at least 6 months prior to Randomization History of inadequate response to treatment for AD with topical medications or for whom topical treatments are otherwise medically inadvisable EASI score ≥ 16 at Screening and at Randomization vIGA AD score ≥ 3 at Screening and at Randomization AD involved BSA ≥ 10% at Screening and at Randomization Key Exclusion Criteria: Any factors that in the Investigator's opinion would predispose the subject to develop an infection Known or suspected congenital or acquired immunodeficiency state, or condition that would compromise the subject's immune status Not able to tolerate SC drug administration Tanning booth use or extended sun exposure that could affect disease severity or interfere with disease assessments within 4 weeks before Randomization
Sites / Locations
- First Oc DermatologyRecruiting
- Center For Dermatology Clinical Research Inc.Recruiting
- Antelope Valley Clinical TrialsRecruiting
- Torrance Clinical Research Institute Inc.Recruiting
- Clinical Science InstituteRecruiting
- Lcc Medical Research Institute, LlcRecruiting
- Floridian Research Institute LlcRecruiting
- Advanced Medical ResearchRecruiting
- Ds Research IndianaRecruiting
- Southern Indiana Clinical TrialsRecruiting
- Ds Research - KentuckyRecruiting
- University of Michigan - Dept. of DermatologyRecruiting
- Henry Ford Medical Center - New Center OneRecruiting
- Medisearch Clinical TrialsRecruiting
- Fife Dermatology PcRecruiting
- Juva Skin & Laser CenterRecruiting
- Darst DermatologyRecruiting
- Wilmington Dermatology CenterRecruiting
- Dermatologists of Southwest OhioRecruiting
- Oregon Medical Research CenterRecruiting
- Tennessee Clinical Research CenterRecruiting
- Reveal Research InstituteRecruiting
- North Texas Center For Clinical ResearchRecruiting
- Progressive Clinical ResearchRecruiting
- Dermatology Clinical Research Center of San AntonioRecruiting
- Enverus Medical ResearchRecruiting
- Simcoderm Medical and Surgical Dermatology CenterRecruiting
- Kingsway Clinical ResearchRecruiting
- DermeffectsRecruiting
- Nectar Research Group, Inc.Recruiting
- North Bay Dermatology CentreRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Experimental
Experimental
Experimental
Placebo Comparator
ANB032 SC Dose 1
ANB032 SC Dose 2
ANB032 SC Dose 3
Placebo
This arm will receive treatment SC
This arm will receive treatment SC
This arm will receive treatment SC
This arm will receive Placebo SC